Suchergebnisse - "Silbermann, Rebecca"

PubPharm (51)

1

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk

enthalten in: Blood cancer journal | 2024

von Callander, N. | Silbermann, R. | Kaufman, J. | +33

2

Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone : Patient-reported outcomes from GRIFFIN

enthalten in: American journal of hematology | 2024

von Silbermann, R. | Laubach, J. | Kaufman, J. | +23

3

Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER) : final report of the multicentre, single-arm, phase 2 trial

enthalten in: The Lancet. Haematology | 2023

von Costa, L. | Chhabra, S. | Medvedova, E. | +14

CommentIn: Lancet Haematol. 2023 Nov;10(11):e867-e868. - PMID 37776871

4

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN) : final analysis of an open-label, randomised, phase 2 trial

enthalten in: The Lancet. Haematology | 2023

von Voorhees, P. | Sborov, D. | Laubach, J. | +25

CommentIn: Lancet Haematol. 2023 Oct;10(10):e788-e789. - PMID 37793762

5

Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell transplantation, and measurable residual disease-response-adapted treatment cessation

enthalten in: EJHaem | 2023

von Silbermann, R. | Schmidt, T. | Bal, S. | +11

6

Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma : Findings from the MASTER and GRIFFIN Trials

enthalten in: Transplantation and cellular therapy | 2023

von Chhabra, S. | Callander, N. | Watts, N. | +34

7

A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma

enthalten in: Future oncology (London, England) | 2023

von Paul, B. | Liedtke, M. | Khouri, J. | +14

8

Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara‐KRd), autologous hematopoietic cell transplantation, and measurable residual disease‐response‐adapted treatment cessation

enthalten in: eJHaem | 2023

von Silbermann, R. | Schmidt, T. | Bal, S. | +11

9

Using Wearable Inertial Sensors to Assess Mobility of Patients With Hematologic Cancer and Associations With Chemotherapy-Related Symptoms Before Autologous Hematopoietic Stem Cell Transplant : Cross-sectional Study

enthalten in: JMIR cancer | 2022

von Skiba, M. | Harker, G. | Guidarelli, C. | +6

10

Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma : Analysis of vascular thrombotic events in the GRIFFIN study

enthalten in: British journal of haematology | 2022

von Sborov, D. | Baljevic, M. | Reeves, B. | +18

1
2
3
4
5
6
Nächster »
[6]